Background: Most studies report using percentage of total daily insulin (TDI) for converting therapy from continuous insulin infusion to subcutaneous insulin in cardiac surgery patients. Few studies have evaluated the efficacy of using body weight to calculate the basal insulin dose.
Objective: To compare the efficacy and safety of dosing insulin glargine by weight versus percentage of TDI in cardiac surgery patients transitioning from continuous insulin infusion to subcutaneous insulin.
Methods: We conducted a prospective, randomized, open-label, pilot study. Study patients who had a preoperative weight less than 100 kg and were receiving at least 6 hours of a continuous insulin infusion were randomized to receive either 50% of their TDI requirement or 0.5 units/kg of glargine as a one-time dose 2 hours before stopping the continuous insulin infusion. All patients were administered subcutaneous corrective insulin. Blood glucose monitoring occurred before each meal, at bedtime, and with morning laboratory tests for 24 hours after administration of the glargine dose.
Results: A total of 200 blood glucose measurements were performed in each group. The percentage of blood glucose measurements in target range (80-140 mg/dL) was similar between the weight-based group and the percentage-based group (66% vs 64%, p = 0.75). Median blood glucose after transition was 120 mg/dL (interquartile range [IQR] 99-147) in the weight-based group compared to 127 mg/dL (IQR 107-149; p = 0.03) in the percentage-based group. The median glargine dose was higher in the weight-based group (41 units; IQR 36-44) than in the weight-based group (24 units; IQR 14-30, p < 0.001). The rate of hypoglycemia (blood glucose <60 mg/dL) was 2.5% in each group.
Conclusions: In this small cohort, dosing insulin glargine by weight proved to be safe, but larger scale studies are needed before adopting weight-based dosing in this patient population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1345/aph.1Q698 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Insomnia is a modifiable risk factor for type 2 diabetes.
Objective: Describe the methodology for the Sleep for Health study, a randomized clinical trial examining the effectiveness of digital cognitive behavioral therapy for insomnia (dCBT-I) in reducing hyperglycemia in 300 people with both insomnia and prediabetes.
Outcomes: Primary outcome is glucose level 2 h after a 75-g glucose load.
Enhanced Metabolic Control in a Pediatric Population with Type 1 Diabetes Mellitus Using Hybrid Closed-Loop and Predictive Low-Glucose Suspend Insulin Pump Treatments.
Pediatr Rep
December 2024
Department of Endocrinology, Diabetes Mellitus, Nutrition and Metabolic Disorders, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Background: Insulin pumps coupled with continuous glucose monitoring sensors use algorithms to analyze real-time blood glucose levels. This allows for the suspension of insulin administration before hypoglycemic thresholds are reached or for adaptive tuning in hybrid closed-loop systems. This longitudinal retrospective study aims to analyze real-world glycemic outcomes in a pediatric population transitioning to such devices.
View Article and Find Full Text PDFEmotional Distress and Cardiovascular Health in Young Adults with Type 1 Diabetes.
J Cardiovasc Dev Dis
December 2024
Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, OH 44106, USA.
Type 1 diabetes (T1D) is a complex chronic condition that places young adults aged 18-31 years at high risk for general and diabetes-related distress and poor cardiovascular health. Both general and diabetes distress are linked to higher A1C, a known risk factor for cardiovascular disease (CVD). The purpose of this cross-sectional quantitative descriptive study was to examine the associations between distress symptoms (general and diabetes) and cardiovascular health while considering covariates in young adults ages 18-31 years with T1D.
View Article and Find Full Text PDFHow Might We Tell if Advances in Diabetes Care and Technology are Helping People to Feel Less Constrained? Introducing the Diabetes Constraints Scale.
J Diabetes Sci Technol
December 2024
Department of Family and Community Medicine, University of California San Francisco, San Francisco, CA, USA.
Background: Recent advances in diabetes care and technology, such as real-time continuous glucose monitoring, can help people live more freely, with more flexibility and fewer constraints, thereby enhancing quality of life (QOL). To date, there has been no validated means for measuring this key psychological dimension. We developed the Diabetes Constraints Scale (DCS) to assess perceived constraints pertaining to diabetes self-management.
View Article and Find Full Text PDFImmune checkpoint inhibitor-associated diabetic ketoacidosis and insulin-dependent diabetes: a case report.
J Med Case Rep
December 2024
Emergency Medicine, Vancouver General Hospital, Vancouver, Canada.
Background: Immunotherapy, including the use of immune checkpoint inhibitors such as nivolumab, is increasingly common in cancer treatment and can lead to various immune-related adverse effects, including rare cases of diabetic ketoacidosis. This case report highlights an unique instance of nivolumab-induced diabetic ketoacidosis in a patient without prior history of diabetes, emphasizing the importance of careful monitoring even in those without traditional risk factors.
Case Presentation: We report a case of a 70-year-old Caucasian male with metastatic esophageal adenocarcinoma who developed diabetic ketoacidosis 3 weeks after stopping nivolumab therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!